Psychiatry Search
Psychiatry Psychiatry
insomnia
INSOMNIA

Insomnia can be either having difficulty in initiating sleep, maintaining sleep or experiencing early morning awakening wherein returning to sleep is not easily attained.

These disturbances can cause significant distress and impairment in daytime functioning.

It is the most prevalent sleep disorder in the general population thus accurate diagnosis and effective treatment is necessary.

Insomnia Signs and Symptoms

Introduction

  • The subjective perception of difficulty in sleep initiation, duration, consolidation, or quality of sleep, occurring despite adequate opportunities for sleep, & resulting in daytime dysfunction
  • Insomnia is the most prevalent sleep disorder in the general population, therefore, it is an important public health problem that needs accurate diagnosis & effective treatment
  • Approximately 6-10% of adults have insomnia & it is more common in females & older adults
    • 30-50% of the population is affected by occasional, short-term insomnia
    • The prevalence of chronic insomnia disorder is estimated to be at least 5-10% in industrialized nations

Risk Factors

  • Increasing age
  • Female gender
  • Medical & psychiatric disease (eg depression, mood disorders)
  • Socioeconomic factors (eg marital separation, unemployment, lower quality of life)
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Psychiatry - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Product Highlight - ADACEL
2 days ago
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Carfilzomib-based triplet regimen a potential upfront treatment for high-risk MM
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Alzheimer’s disease prevention: Can antidepressants lend a hand?
Jairia Dela Cruz, Yesterday
The selective serotonin reuptake inhibitor escitalopram holds promise in the prevention of Alzheimer’s disease, reducing amyloid-β-42 levels in cerebrospinal fluid and brain tissue in older adults with normal cognitive function, according to recent evidence.
Empagliflozin not just another SGLT2i: Cardio-renal benefits extend to HF with or without diabetes
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.